CNI vs PCAR

CNI presents a stable financial profile with a Piotroski F-Score of 4/9 and an absent Altman Z-Score, indicating a 'stable' but not 'strong' health trajectory. While the company boasts exceptional operating margins (42.41%) and a strong ROE (22.15%), it is currently trading at a significant premium to its Graham Number ($56.63), though it remains below its growth-based intrinsic value ($133.51). The disconnect between sluggish revenue growth (2.4%) and a high PEG ratio (2.52) suggests the stock may be overvalued relative to its current growth rate. Overall, CNI is a high-quality industrial compounder currently facing valuation headwinds and mediocre short-term financial momentum.

PACCAR exhibits strong fundamental health with a Piotroski F-Score of 7/9 and robust liquidity ratios, yet it faces a severe valuation disconnect. The current price of $127.20 trades at a significant premium to both the Graham Number ($61.0) and the growth-based Intrinsic Value ($31.57). While the balance sheet is a fortress, the company is currently grappling with sharp declines in YoY revenue (-13.7%) and earnings (-35.9%), coupled with bearish insider activity from the CEO and CFO.